# A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

> **NCT04284761** · PHASE1 · COMPLETED · sponsor: **Alessa Therapeutics Inc.** · enrollment: 17 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Lower Urinary Tract Symptoms

## Interventions

- **COMBINATION_PRODUCT:** Bicalutamide implant

## Key facts

- **NCT ID:** NCT04284761
- **Lead sponsor:** Alessa Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-11
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04284761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04284761, "A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04284761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*